MediciNova, Inc. (MNOV) News
Filter MNOV News Items
MNOV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MNOV News Highlights
- For MNOV, its 30 day story count is now at 14.
- Over the past 27 days, MNOV's stories per day has been in a clear downtrend, falling by about 0.46 per 4 days.
- MN and AUD are the most mentioned tickers in articles about MNOV.
Latest MNOV News From Around the Web
Below are the latest news stories about Medicinova Inc that investors may wish to consider to help them evaluate MNOV as an investment opportunity.
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in DrugsLA JOLLA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced MN-166 (ibudilast) was discussed as one of the promising pharmacological agents for the treatment of alcohol use disorder (AUD) in the journal Drugs. The publication entitled “Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder,” co-authored by Me |
The past three years for MediciNova (NASDAQ:MNOV) investors has not been profitableInvesting in stocks inevitably means buying into some companies that perform poorly. Long term MediciNova, Inc... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayRise and shine, trader! |
MediciNova nabs new patent in Korea for MN-001 for treatment of blood cholesterolMediciNova (MNOV) received a new patent from the Korean Intellectual Property Office which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia, |
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in KoreaLA JOLLA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a new patent from the Korean Intellectual Property Office which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent appli |
MediciNova stock jumps after securing Canada patent for MN-001/002 for hepatic ballooningMediciNova (MNOV) gains 9.7% premarket after receiving a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers |
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in CanadaLA JOLLA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for hepatic ballooning. Once issued, the patent maturing from this a |
MediciNova receives new European patent for ibudilast for alcohol use disorderMediciNova (MNOV) has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of |
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in EuropeLA JOLLA, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of alcohol use disorder. Once issued, the patent maturing from this allowed patent application is e |
MediciNova secures new European patent for MN-001 and MN-002 for hepatic ballooningMediciNova (MNOV) that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a |